Čereškevičius Darius, Čiapienė Ieva, Aldujeli Ali, Zabiela Vytautas, Lesauskaitė Vaiva, Zubielienė Kristina, Raškevičius Vytautas, Žaliaduonytė Diana, Unikas Ramūnas, Pranevičius Robertas, Simanauskas Ignas, Bakšytė Giedrė, Tamošiūnas Abdonas, Lukšienė Dalia, Šakalytė Gintarė, Tatarūnas Vacis
Institute of Cardiology, Lithuanian University of Health Sciences, Sukileliu 15, 50103 Kaunas, Lithuania.
Department of Cardiology, Kaunas Hospital of the Lithuanian University of Health Sciences, Hipodromo 13, 45130 Kaunas, Lithuania.
Int J Mol Sci. 2025 Mar 6;26(5):2337. doi: 10.3390/ijms26052337.
Hypercholesterolemia, characterized by elevated levels of low-density lipoprotein cholesterol (LDL-C), along with inflammation, is a well-known risk factor for developing atherosclerosis and coronary artery disease (CAD). Many patients with hypercholesterolemia may carry inherited genetic variants that are not part of the commonly recognized mutations in the , , , and genes. These genetic variants may have cumulative effects that contribute to increased LDL-C levels and CAD development. The polygenic risk score (PRS) may provide an essential tool for evaluating an individual's genetic predisposition to these conditions. This pilot study aimed to investigate the impact of the PRS calculated from specific single nucleotide polymorphisms (SNPs) associated with LDL cholesterol (LDL-C)-namely, , , , , , and -on LDL-C levels in both healthy individuals with elevated LDL-C levels (>2.6 mmol/L) and those diagnosed with ST-segment elevation myocardial infarction (STEMI). A total of 61 healthy individuals with high LDL-C levels (>2.6 mmol/L) and 93 STEMI patients were selected for the study. The High-Resolution Melting Polymerase Chain Reaction (HRM PCR) method was adopted and sequencing techniques were employed to identify the specific single nucleotide polymorphisms (SNPs) of interest. The patient group exhibited a PRS of 0.824 (with a range of -0.62 to 1.174) compared to 0.674 (range: -0.176 to 0.974) in healthy individuals, indicating a higher genetic predisposition to elevated LDL-C levels ( = 0.001) in patients. Interestingly, patients had lower LDL-C concentrations than healthy individuals. Additionally, a more significant number of patients were past smokers and statin users. The PRS calculations revealed that patients with a higher PRS had increased odds of experiencing an MI, with an odds ratio of 12.044 (95% confidence interval: 1.551-93.517, = 0.017). Similarly, smokers showed even higher odds, with an odds ratio of 24.962 (95% CI: 7.171-86.890, < 0.001). Among healthy individuals, those with a higher PRS had increased odds of having an LDL-C concentration greater than 4.9 mmol/L (odds ratio: 20.391, 95% CI: 1.116-358.486, = 0.039). However, no significant association was found between the PRS and LDL-C levels in the patient group during hospitalization ( = 0.782). This pilot study shows that PRS can be employed to evaluate the risk of MI and to estimate concentrations greater than 4.9 mmol/L LDL-C in healthy individuals.
高胆固醇血症,其特征是低密度脂蛋白胆固醇(LDL-C)水平升高,同时伴有炎症,是动脉粥样硬化和冠状动脉疾病(CAD)发展的众所周知的危险因素。许多高胆固醇血症患者可能携带遗传变异,这些变异并非常见的、、、和基因中的公认突变的一部分。这些遗传变异可能具有累积效应,导致LDL-C水平升高和CAD发展。多基因风险评分(PRS)可能为评估个体对这些疾病的遗传易感性提供一个重要工具。这项初步研究旨在调查从与低密度脂蛋白胆固醇(LDL-C)相关的特定单核苷酸多态性(SNP)——即、、、、、和——计算得出的PRS对LDL-C水平升高的健康个体(>2.6 mmol/L)和诊断为ST段抬高型心肌梗死(STEMI)的个体的影响。总共61名LDL-C水平高(>2.6 mmol/L)的健康个体和93名STEMI患者被选入该研究。采用高分辨率熔解聚合酶链反应(HRM PCR)方法并运用测序技术来鉴定感兴趣的特定单核苷酸多态性(SNP)。患者组的PRS为0.824(范围为-0.62至1.174),而健康个体为0.674(范围:-0.176至0.974),表明患者中LDL-C水平升高的遗传易感性更高(=0.001)。有趣的是,患者的LDL-C浓度低于健康个体。此外,更多患者既往吸烟且使用他汀类药物。PRS计算显示,PRS较高的患者发生心肌梗死的几率增加,比值比为12.044(95%置信区间:1.551 - 93.517,=0.017)。同样,吸烟者的几率更高,比值比为24.962(95% CI:7.171 - 86.890,<0.001)。在健康个体中,PRS较高的个体LDL-C浓度大于4.9 mmol/L的几率增加(比值比:20.391,95% CI:1.116 - 358.486,=0.039)。然而,在住院期间患者组中未发现PRS与LDL-C水平之间存在显著关联(=0.782)。这项初步研究表明,PRS可用于评估心肌梗死风险并估计健康个体中LDL-C浓度大于4.9 mmol/L的情况。